COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #75 of 230
6/30 Late treatment study
Mikami et al., J. Gen. Intern. Med., doi:10.1007/s11606-020-05983-z (Peer Reviewed)
Risk Factors for Mortality in Patients with COVID-19 in New York City
Source   PDF   Share   Tweet
HCQ decreases mortality, HR 0.53 (CI 0.41–0.67). IPTW adjustment does not significantly change HR 0.53 (0.41-0.68). Retrospective 6,000 patients in New York City.

Mikami et al., 6/30/2020, retrospective, USA, North America, peer-reviewed, 7 authors.
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 575 of 2077 (27.7%), control 231 of 743 (31.1%), adjusted per study.
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.
Submit